Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes. - Wikidata - wikimedia - TriplyDB

Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.

Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.

http://www.wikidata.org/entity/Q48435795

about

Fingolimod for the treatment of neurological diseases-state of play and future perspectives The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis Alterations of the Ceramide Metabolism in the Peri-Infarct Cortex Are Independent of the Sphingomyelinase Pathway and Not Influenced by the Acid Sphingomyelinase Inhibitor Fluoxetine Sphingosine 1 Phosphate at the Blood Brain Barrier: Can the Modulation of S1P Receptor 1 Influence the Response of Endothelial Cells and Astrocytes to Inflammatory Stimuli?Immunological mechanism of action and clinical profile of disease-modifying treatments in multiple sclerosis.Dysregulation of lysophosphatidic acids in multiple sclerosis and autoimmune encephalomyelitis.Ozanimod (RPC1063) is a potent sphingosine-1-phosphate receptor-1 (S1P1 ) and receptor-5 (S1P5 ) agonist with autoimmune disease-modifying activity.Cardiovascular effects of fingolimod: A review article.Astroglial PGC-1alpha increases mitochondrial antioxidant capacity and suppresses inflammation: implications for multiple sclerosis Chronic ethanol consumption profoundly alters regional brain ceramide and sphingomyelin content in rodents Exogenous S1P Exposure Potentiates Ischemic Stroke Damage That Is Reduced Possibly by Inhibiting S1P Receptor Signaling.Mechanism of Action and Clinical Potential of Fingolimod for the Treatment of Stroke.Interferon-Beta Increases Plasma Ceramides of Specific Chain Length in Multiple Sclerosis Patients, Unlike Fingolimod or Natalizumab.A biological perspective of CSF lipids as surrogate markers for cognitive status in HIV Fingolimod for the treatment of relapsing multiple sclerosis.Pharmacokinetic evaluation of fingolimod for the treatment of multiple sclerosis.Molecular pharmacodynamics of new oral drugs used in the treatment of multiple sclerosis Role of sphingomyelinases in neurological disorders.Altered Sphingolipid Balance in Capillary Cerebral Amyloid Angiopathy.Fingolimod exerts neuroprotective effects in a mouse model of intracerebral hemorrhage Cellular distribution of glucose and monocarboxylate transporters in human brain white matter and multiple sclerosis lesions.FTY720 attenuates excitotoxicity and neuroinflammation.Acid sphingomyelinase deficiency enhances myelin repair after acute and chronic demyelination Cardiac Safety of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator: Results of a Thorough QT/QTc Study.Differential regulation of sphingolipid metabolism in plasma, hippocampus, and cerebral cortex of mice administered sphingolipid modulating agents.Astrocyte-derived retinoic acid: a novel regulator of blood-brain barrier function in multiple sclerosis.Functional antagonism of sphingosine-1-phosphate receptor 1 prevents cuprizone-induced demyelination.Deletion of MCP-1 Impedes Pathogenesis of Acid Ceramidase Deficiency.C2-ceramide influences alveolar epithelial barrier function by downregulating Zo-1, occludin and claudin-4 expression.Fingolimod may support neuroprotection via blockade of astrocyte nitric oxide.Bioactive Lipids and Chronic Inflammation: Managing the Fire Within.[New therapeutic strategies for remyelination in multiple sclerosis].Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis.Metabolic Dysfunction and Peroxisome Proliferator-Activated Receptors (PPAR) in Multiple Sclerosis.

P2860

Q27026175-324D7809-EDBA-43A0-9F0D-08905EA85B53 Q28073377-817C4E90-AD8F-40D2-8EA7-41364778F6B5 Q28270227-B32F0817-354E-4B97-9A36-625312F1B26B Q28546716-55A0B522-DDC6-4C9C-9A7C-2A9AED78FC81 Q33755345-1FBCFBEE-263B-4093-9A68-1D10B4A7A734 Q33759830-C7A5343C-24C0-4843-ACE2-9285A6C54FCC Q34518822-35D8BCBC-3201-4709-BB03-CAA96782F9D2 Q34558943-0F2E8D2F-7D2A-4184-90AC-A324CD303ABA Q34720644-2719936F-AB4C-4D23-8864-751E3D62FCED Q35212956-2DDE8376-9FF5-4673-9B74-28C1B0104BC8 Q36241484-EE08634F-8F1F-467C-8281-797B33C254D0 Q37209163-8330D6E0-FFBA-483D-940A-C151113AAF3D Q37389500-A150D3AC-942A-471B-986A-D984C25662C8 Q37541514-3902081F-DE07-49DB-89E5-077FBBB433B5 Q38112209-B5648CDD-18A3-4C12-8986-854EA334D06B Q38192006-9174A151-432A-44CC-94F9-A1F9ADBC775E Q38216015-A71B5248-3606-423C-8354-E0D83206AD79 Q38560939-219E7F49-10DE-4682-B866-C51F3A295E08 Q38818321-91F686AE-9796-4539-9D60-A5DABE31972D Q38873721-51E4518D-10E2-476A-A6DD-EC4B22B2DCA0 Q39009182-CB613C2F-7430-48AE-8917-C0E6D0AC6289 Q40613316-8301C1E8-B854-4ECD-A9E2-CFAC322EC43F Q42221029-A31E0A0B-3488-4C70-8990-AC2B56F537BB Q46025818-B75C7B5E-38C0-42F7-835C-C3DE75817638 Q46426783-CDB9F097-0C84-407F-94E5-9ABC8A01B360 Q46848816-797545F6-B0FB-4E5F-8B47-A2D1E6FDA56F Q47343678-30C24F11-D5BD-4F8F-AE34-4C1478A8762B Q47833651-9B246EF9-1B74-4451-8254-A01DF0AB8EE1 Q48005842-A74724F6-E7E4-41C0-BC79-89067DBB4C28 Q48649157-7848FC11-142E-4D09-BAC4-8A075CC0B5EB Q49679435-D21DF85C-6D33-4F97-9996-F21E96E4D66F Q53448928-14559CFF-967E-466D-92BA-D42A8E97AD80 Q53669235-D2B96074-7692-4822-82FB-874548D3AB66 Q55561652-89AF415F-E28A-4EB5-9B4D-59716F7D0E46

P2860

Fingolimod attenuates ceramide-induced blood-brain barrier dysfunction in multiple sclerosis by targeting reactive astrocytes.

http://www.wikidata.org/entity/Q48435795

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh-hant

name

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@en

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@nl

type

label

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@en

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@nl

prefLabel

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@en

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@nl

P1433

Q48435795-5B984103-D256-4B1A-89C8-C4A34C2AAD97

P1476

Q48435795-74CE11A0-BC4E-4CD6-9529-4BF7FF7BA673

P2093

Q48435795-1605405A-5770-4461-8F4B-713BD7A9CF84

Q48435795-1DE4822E-0CFD-48FA-870A-A69C7E0344B0

Q48435795-5EC4AD2C-2A34-48E5-9715-2573F99782B9

Q48435795-5FE5DEF5-AC5D-4FEB-B53D-8BDEE7304A92

Q48435795-99DB94A2-6B07-456F-8DD0-20672C894F0B

Q48435795-9A31D3A2-F6E1-4210-98D2-9522653ADC8A

Q48435795-9E989444-642D-4FD8-B789-94E91D1CED83

Q48435795-CEA7AE42-C52E-41F2-9F23-A826D2FE517D

Q48435795-DA413566-0594-4D86-B0F9-DEF788116391

Q48435795-E95CADC5-F5A9-4AB1-BA53-B3E73076F7BF

P2860

Q48435795-010A7F74-3C61-4C54-A4A2-64EB142A0180

Q48435795-09DB3065-7040-41EB-959D-3268AB5978B0

Q48435795-0E9F2340-D45A-4A2D-90A2-22D59A112ACB

Q48435795-11E7B981-7EF3-41A3-AA66-8895502935EB

Q48435795-123AF955-E8FC-4EB4-A44A-D300C4DBA625

Q48435795-171A4B06-206D-4965-B32E-F022A421DD5C

Q48435795-19155489-E2ED-4EFC-8EAF-8B3A3E2DFE32

Q48435795-20A8CAB7-25A3-4043-8EA7-89F04C8FF352

Q48435795-25B5B28F-5DCD-4F6E-A26E-A1ABD9665B17

Q48435795-31D67D1E-5059-453D-9297-70BFC46EFB51

P2888

Q48435795-DF513A17-D879-4DAA-A15B-F10A0935FFE4

P304

Q48435795-887B362D-9ED0-4CC9-8F53-7523F02186ED

P31

Q48435795-631EF93B-614A-4126-AFDA-0702CDED73ED

P356

Q48435795-1F5576B7-B5B9-4CD0-888F-77288972EB54

P433

Q48435795-BB2698FC-3798-48E1-AF5D-214E651C291F

P478

Q48435795-80F76959-DC0C-4376-BCAA-6AC134D7D911

P50

Q48435795-69EBB6AB-43D5-41C6-AE26-2DE80CB4D85D

P577

Q48435795-801AD62B-5A7E-4759-98C3-E94B02DE4F40

P698

Q48435795-3A87EDEE-7F3B-4067-BEE7-F8211CF6E21B

P921

Q48435795-B0201CB0-AD3A-4497-9884-6943127D84ED

Q48435795-C08E2565-5A77-490D-94BD-3D29F4B6639B

Q48435795-f5f1a4fa-a048-48be-b132-cfa7009e1a0d

P356

S00401-012-1014-4

P1433

Acta Neuropathologica

P1476

Fingolimod attenuates ceramide ...... targeting reactive astrocytes.

@en

P2093

Arie Reijerkerk

http://www.w3.org/2001/XMLSchema#string

Bert van het Hof

http://www.w3.org/2001/XMLSchema#string

Christine Dijkstra

http://www.w3.org/2001/XMLSchema#string

Gijs Kooij

http://www.w3.org/2001/XMLSchema#string

Jack van Horssen

http://www.w3.org/2001/XMLSchema#string

Maarten E Witte

http://www.w3.org/2001/XMLSchema#string

Melissa A Lopes-Pinheiro

http://www.w3.org/2001/XMLSchema#string

Nick Dekker

http://www.w3.org/2001/XMLSchema#string

Paul van van der Valk

http://www.w3.org/2001/XMLSchema#string

Philip G Nijland

http://www.w3.org/2001/XMLSchema#string

P2860

A defect of sphingolipid metabolism modifies the properties of normal appearing white matter in multiple sclerosis

FTY720 inhibits ceramide synthases and up-regulates dihydrosphingosine 1-phosphate formation in human lung endothelial cells

Mutations in SPTLC1, encoding serine palmitoyltransferase, long chain base subunit-1, cause hereditary sensory neuropathy type I

Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide

Structure and function of the blood-brain barrier

Ceramide triggers budding of exosome vesicles into multivesicular endosomes

Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1

Acid sphingomyelinase activity triggers microparticle release from glial cells.

Neurons and oligodendrocytes recycle sphingosine 1-phosphate to ceramide: significance for apoptosis and multiple sclerosis

Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS.

P2888

s00401-012-1014-4

P304

397-410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00401-012-1014-4

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Helga E de Vries

P577

2012-07-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22810490

http://www.w3.org/2001/XMLSchema#string

P921

blood–brain barrier

multiple sclerosis